Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RCUS Arcus Biosciences Inc.

休市中 10-09 16:00:00 EDT

24.41

+0.58

+2.43%

盘后24.41

+0.000.00%

19:30 EDT

最高24.58	最低23.75	成交量79.52万
今开23.89	昨收23.83	日振幅3.48%
总市值31.08亿	流通市值21.93亿	总股本1.27亿
成交额1,934万	换手率0.89%	流通股本8,984万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RCUS","market":"US","secType":"STK","nameCN":"Arcus Biosciences Inc.","latestPrice":24.41,"timestamp":1791576000000,"preClose":23.83,"halted":0,"volume":795188,"hourTrading":{"tag":"盘后","latestPrice":24.41,"preClose":24.41,"latestTime":"19:30 EDT","volume":31457,"amount":767865.37,"timestamp":1791588606659,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024339068401175067,"floatShares":89836387,"shares":127333400,"eps":-3.864072,"marketStatus":"休市中","change":0.58,"latestTime":"10-09 16:00:00 EDT","open":23.89,"high":24.58,"low":23.75,"amount":19344630.717808,"amplitude":0.03483,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.864072,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1521086400000,"exchange":"NYSE","adjPreClose":23.83,"preHourTrading":{"tag":"盘前","latestPrice":23.8467,"preClose":23.83,"latestTime":"08:47 EDT","volume":1,"amount":23.8467,"timestamp":1791550059109,"change":0.0167,"changeRate":0.000701,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.41,"preClose":24.41,"latestTime":"19:30 EDT","volume":31457,"amount":767865.37,"timestamp":1791588606659,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5913156198251353,"impliedVol":1.0227,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/RCUS/wiki","defaultTab":"wiki","newsList":[{"id":"1113768181","title":"财报前瞻｜Arcus Biosciences Inc.营收预计降25.80%，市场偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1113768181","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113768181?lang=zh_cn&edition=full","pubTime":"2026-07-29 13:17","pubTimestamp":1785302261,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.将于2026年08月05日（盘后）发布最新季度财报，市场关注收入波动与亏损收窄节奏，以及近期合作推进对财务前景的影响。上季度Arcus Biosciences Inc.收入为1,700.00万美元，同比下降39.29%；归属于母公司股东的净利润为-1.28亿美元，环比变动为-20.75%；毛利率与净利率数据未披露；调整后每股收益为-1.02美元，同比改善10.53%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Arcus Biosciences Inc.营收预计降25.80%，市场偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172881732","title":"Arcus Biosciences与Aveo达成替沃扎尼供应协议；Arcus资助研究；双方保留化合物权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1172881732","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172881732?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:37","pubTimestamp":1784752660,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.（RCUS）与Aveo Pharmaceuticals已就抗癌药物替沃扎尼（tivozanib）的供应达成协议。根据协议条款，Aveo将负责提供该药物，而Arcus将资助并主导相关临床研究。\n值得关注的是，双方在合作中均保留了各自对相关化合物的完整权利。这一安排为两家公司在未来探索其他潜在开发路径保留了灵活性。\n此次合作旨在推进替沃扎尼在特定癌症适应症中的临床开发。双方资源的整合有望加速该疗法的研究进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165046970","title":"根据协议条款，Summit将提供Ivonescimab，Arcus将主导并资助联合研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1165046970","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165046970?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:33","pubTimestamp":1784752392,"startTime":"0","endTime":"0","summary":"根据双方达成的协议，Summit公司将负责提供Ivonescimab，而Arcus Biosciences Inc.则将主导并全额资助一项联合疗法的临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182074805","title":"Arcus Biosciences Inc.：双方将共同承担研究成本，各自保留其分子的开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1182074805","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182074805?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:32","pubTimestamp":1784752343,"startTime":"0","endTime":"0","summary":"根据合作协议，Arcus Biosciences Inc. 将与合作伙伴均摊相关研究费用。协议同时明确，双方将各自保留其特定分子资产的开发权及商业化权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102087249","title":"Arcus Biosciences Inc.：与合作伙伴的临床试验初步数据预计2027年中出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=1102087249","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102087249?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:32","pubTimestamp":1784752334,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.近日披露，其与合作伙伴共同推进的一项临床试验，预计将在2027年中期首次产出初步研究数据。这项临床合作旨在评估特定疗法的潜力与安全性，其数据的生成将成为后续研发决策的关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180108436","title":"Arcus Biosciences与Summit Therapeutics达成临床试验合作，评估Casdatifan联合Ivonescimab治疗肾癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1180108436","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180108436?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:32","pubTimestamp":1784752323,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc. (RCUS) 与 Summit Therapeutics PLC (SMMT) 宣布达成一项临床试验合作，旨在评估Casdatifan与Ivonescimab联合疗法在肾癌治疗中的潜力。该合作将探索两种研究性药物的协同作用，为肾细胞癌患者开发新的治疗选择。双方将整合各自的研发资源与专业知识，共同推进此项临床研究，以期加速创新疗法的开发进程。这项合作标志着两家公司在肿瘤免疫治疗领域深化探索，致力于应对未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","RCUS","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182485999","title":"Arcus Biosciences宣布临床合作及供应协议，评估Casdatifan联合PD-L1/VEGF-A双特异性免疫调节剂治疗肾癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1182485999","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182485999?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:02","pubTimestamp":1780488175,"startTime":"0","endTime":"0","summary":"Arcus Biosciences宣布了一项临床合作与供应协议，旨在评估其药物Casdatifan与一种靶向PD-L1及VEGF-A的双特异性免疫调节剂联合用药方案在治疗肾细胞癌中的潜力。此项合作聚焦于推进针对肾癌的新型联合疗法开发，标志着公司在肿瘤免疫治疗组合策略领域的又一重要布局。协议的具体财务条款及合作方细节目前尚未披露。该临床评估预计将探索这种创新联合疗法在改善晚期肾癌患者临床结局方面的安全性与初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156946115","title":"财报前瞻｜Arcus Biosciences Inc.本季度营收预计同比降19.31%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1156946115","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156946115?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:08","pubTimestamp":1777352882,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.将于2026年05月05日（盘后）披露财报，市场聚焦营收与亏损收窄节奏及关键管线节点。一致预期显示，本季度公司营收预计为2,948.44万美元，同比下降19.31%；调整后每股收益预计为-0.88美元，同比改善14.94%；息税前利润预计为-1.08亿美元，同比改善5.78%。本季度一致预期指向营收2,948.44万美元，同比下滑19.31%，核心变量仍是合作与许可的确认节奏与规模，该业务的阶段性波动会直接影响单季收入表现与利润率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Arcus Biosciences Inc.本季度营收预计同比降19.31%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724630","title":"Arcus Biosciences(RCUS)跌超5% 与吉利德(GILD)合作的肺癌三期研究因无效性而停止","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724630","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628724630?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:05","pubTimestamp":1776697554,"startTime":"0","endTime":"0","summary":"金吾财讯 | Arcus Biosciences(RCUS)跌5.63%，报2.885美元。消息面上，Arcus Biosciences周一表示，在独立数据监测委员会因无效性建议停止试验后，公司已终止其与吉利德科学(GILD)合作开展的针对转移性非小细胞肺癌的三期STAR-121研究。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1934455277.USD","BK4578","LU0122379950.USD","LU0114720955.EUR","LU1674673691.USD","SG9999015952.SGD","LU0320765992.SGD","BK4583","LU0965509010.AUD","BK4568","LU2468319806.SGD","LU1023059063.AUD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU1585245621.USD","LU2089984988.USD","LU0289739699.SGD","LU1571399168.USD","LU0823416689.USD","LU2324357040.USD","LU1430594728.SGD","LU0965509101.SGD","IE00B19Z3B42.SGD","LU0882574055.USD","LU1934455863.HKD","LU0861579265.USD","LU1839511570.USD","GILD","IE00BKVL7J92.USD","BK4585","SG9999015978.USD","LU0234570918.USD","LU2087621335.USD","SG9999015945.SGD","LU1037948541.HKD","IE00BSNM7G36.USD","BK4139","LU2112291526.USD","LU0965509283.SGD","BK4550","BK4588","LU0058720904.USD","LU1778281490.HKD","RCUS","LU1934455194.USD","LU1037948897.HKD","IE0002270589.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143884291","title":"Arcus Biosciences与吉利德合作协议期权权利将于2026年7月14日到期——美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1143884291","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143884291?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:04","pubTimestamp":1776686642,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件显示，Arcus Biosciences Inc.与吉利德科学此前达成的合作协议中，吉利德科学所持有的期权权利即将于2026年7月14日正式终止。\n这一关键时间节点的确认，标志着两家生物技术公司在肿瘤治疗领域战略合作关系的阶段性调整。期权权利的到期可能为双方未来合作模式带来新的变数，同时也为市场观察者提供了审视生物医药企业合作动态的重要窗口。\n合作协议条款的变更往往预示着企业战略方向的微妙转变。此次期权期限的明确，不仅关系到双方现有研发项目的权益分配，更可能对后续资本市场的估值预期产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","IE00B3T34201.USD","LU0889565916.HKD","LU1066053197.SGD","LU1934455863.HKD","LU1674673691.USD","LU1023059063.AUD","BK4139","LU0122379950.USD","LU0823416689.USD","LU0965508806.USD","LU2324357040.USD","RCUS","LU0965509010.AUD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","SG9999015952.SGD","LU2087621335.USD","LU1839511570.USD","LU0882574055.USD","LU1037948541.HKD","SG9999015978.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4578","IE0002270589.USD","LU1061106388.HKD","BK4568","LU0058720904.USD","LU1057294990.SGD","LU1571399168.USD","BK4550","BK4583","GILD","LU1778281490.HKD","BK4588","LU1066051498.USD","LU0861579265.USD","LU1934455277.USD","LU0320765992.SGD","LU0234570918.USD","SG9999015945.SGD","LU1934455194.USD","IE00B19Z3581.USD","LU1585245621.USD","BK4532","LU2089984988.USD","LU0114720955.EUR","LU1674673428.USD","IE00BKVL7J92.USD","LU1037948897.HKD","LU0965509283.SGD","LU0109394709.USD","BK4566","BK4585","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271566","title":"Arcus Biosciences, Inc.盘中异动 早盘大幅跳水5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518271566?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:23","pubTimestamp":1741616619,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时23分，Arcus Biosciences, Inc.股票出现波动，股价快速下跌5.22%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3406.15%、721.29%、415.10%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665940","title":"Arcus Biosciences, Inc.盘中异动 临近收盘大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516665940?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:37","pubTimestamp":1741034235,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时37分，Arcus Biosciences, Inc.股票出现波动，股价急速跳水5.05%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Celularity Inc C/Wts 16/07/2026 涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为215.44%、187.68%、163.59%，振幅较大的相关个股有Radiopharm Theranostics Limited、Entero Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为119.50%、70.53%、64.88%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516557562","title":"Arcus Biosciences, Inc.2024财年实现净利润-2.83亿美元，同比增加7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516557562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516557562?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844883,"startTime":"0","endTime":"0","summary":"3月2日，Arcus Biosciences, Inc.公布财报，公告显示公司2024财年净利润为-2.83亿美元，同比增加7.82%；其中营业收入为2.58亿美元，同比增加120.51%，每股基本收益为-3.14美元。机构评级：截至2025年3月2日，当前有11家机构对Arcus Biosciences, Inc.目标价做出预测，其中目标均价为32.55美元，其中最低目标价为17.00美元，最高目标价为46.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378385","title":"Arcus Biosciences, Inc.盘中异动 早盘股价大涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514378385?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:30","pubTimestamp":1740753029,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时30分，Arcus Biosciences, Inc.股票出现异动，股价大幅上涨5.77%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Virpax Pharmaceuticals, Inc.、Bioxcel Therapeutics, Inc.、Ensysce Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.20%、239.09%、53.23%，振幅较大的相关个股有Tiziana Life Sciences Ltd、Aardvark Therapeutics, Inc.、Lexeo Therapeutics, Inc.，振幅分别为8.85%、6.22%、4.85%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156992500","title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156992500","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156992500?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:13","pubTimestamp":1740582780,"startTime":"0","endTime":"0","summary":"今日盘中,Arcus Biosciences大涨13.38%,引发市场高度关注。有消息指出,这次RCUS盘中大涨的主因可能来自以下两方面:首先,券商H.C. Wainwright将该股评级从\"中性\"上调至\"买入\",并将目标价从18美元大幅上调至24美元。该行分析师认为,RCUS的实验性药物casdatifan有望成为治疗一种名为\"透明细胞肾细胞癌\"的肾癌类型的二线疗法,看好其未来前景。其次,RCUS刚刚公布的2025年第四季度财报数据也令投资者振奋。良好的财报数据反映出公司运营情况向好,增强了市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856450","title":"Arcus Biosciences, Inc.盘中异动 股价大涨11.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856450?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:33","pubTimestamp":1740580398,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时33分，Arcus Biosciences, Inc.股票出现波动，股价大幅上涨11.23%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Channel Therapeutics Corporation、Nutriband Inc C/Wts 、Immunoprecise Antibodies Ltd.涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Psyence Biomedical Ltd.较为活跃，换手率分别为122.60%、92.20%、74.72%，振幅较大的相关个股有Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.、Organovo Holdings, Inc.，振幅分别为16.86%、14.35%、13.39%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106972136","title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106972136","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106972136?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:38","pubTimestamp":1740519531,"startTime":"0","endTime":"0","summary":"Arcus Biosciences 报告季度每股亏损$，优于分析师普遍预期的$，涨幅为21.97%。与去年同期每股亏损$相比，亏损减少4.63%。与去年同期销售额3100万美元相比，增长了16.13%。以上内容来自Benzinga Earnings专栏，原文如下：Arcus Biosciences  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 21.97 percent. This is a 4.63 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $36.00 million which beat the analyst consensus estimate of $28.90 million by 24.57 percent.  This is a 16.13 p","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513773346","title":"Arcus Biosciences, Inc.盘中异动 早盘快速下跌5.01%报10.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513773346?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:27","pubTimestamp":1740410825,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时27分，Arcus Biosciences, Inc.股票出现异动，股价大幅下跌5.01%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为200.89%、84.63%、27.77%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296986","title":"Arcus Biosciences, Inc.盘中异动 急速上涨6.04%报11.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296986?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148289,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Arcus Biosciences, Inc.股票出现波动，股价快速拉升6.04%。截至发稿，该股报11.39美元/股，成交量8.1623万股，换手率0.08%，振幅1.49%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Osr Holdings, Inc.、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.26%、61.10%、18.92%，振幅较大的相关个股有Osr Holdings, Inc.、蓝鸟生物、Gain Therapeutics, Inc.，振幅分别为14.17%、11.05%、10.21%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223129a24eb022&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223129a24eb022&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512485174","title":"Arcus Biosciences, Inc.盘中异动 早盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512485174?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:56","pubTimestamp":1739976976,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时56分，Arcus Biosciences, Inc.股票出现波动，股价快速上涨5.02%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225616abd504ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225616abd504ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcusbio.com","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.1432},{"period":"3month","weight":-0.1559},{"period":"6month","weight":0.0927},{"period":"1year","weight":0.6102},{"period":"ytd","weight":0.0243}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcus Biosciences, Inc.于2015年4月30日在特拉华州成立。它们是一家临床阶段的生物制药公司，致力于通过利用开发不足的生物机会创造创新的癌症免疫疗法。具体而言，他们针对特征明确的生物学途径，并提供重要的科学数据支持其调节对癌症的免疫反应的重要性，并且无论是在开发中的分子还是在存在具有次优分布的分子。为了利用这些途径，他们建立了强大而高效的发现能力，以创建和优化高度分化的小分子免疫肿瘤产品候选物。自2015年成立以来，他们已经建立了广泛的小分子和抗体产品候选组合，他们计划共同开发内部组合产品。他们已经启动了两项最先进的候选产品的临床试验，这两种产品预计将在2018年产生数据，并且他们预计在2019年上半年将从他们的第一批产品组合中获得临床数据。他们计划推出两种附加产品候选人到2018年底进入临床试验阶段。Arcus团队的成员共同工作了10多年，在Tularik Inc.，Amgen，Inc.和Flexus Biosciences，Inc.等公司中发现创新的小分子产品候选人。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.062454},{"month":2,"riseRate":0.625,"avgChangeRate":0.1292},{"month":3,"riseRate":0.375,"avgChangeRate":-0.076763},{"month":4,"riseRate":0.444444,"avgChangeRate":0.079583},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.024582},{"month":6,"riseRate":0.444444,"avgChangeRate":0.007355},{"month":7,"riseRate":0.444444,"avgChangeRate":0.003642},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059307},{"month":9,"riseRate":0.444444,"avgChangeRate":0.007811},{"month":10,"riseRate":0.333333,"avgChangeRate":0.006594},{"month":11,"riseRate":0.875,"avgChangeRate":0.177539},{"month":12,"riseRate":0.25,"avgChangeRate":-0.02808}],"exchange":"NYSE","name":"Arcus Biosciences Inc.","nameEN":"Arcus Biosciences Inc."},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcus Biosciences Inc.,RCUS,Arcus Biosciences Inc.股票,Arcus Biosciences Inc.股票老虎,Arcus Biosciences Inc.股票老虎国际,Arcus Biosciences Inc.行情,Arcus Biosciences Inc.股票行情,Arcus Biosciences Inc.股价,Arcus Biosciences Inc.股市,Arcus Biosciences Inc.股票价格,Arcus Biosciences Inc.股票交易,Arcus Biosciences Inc.股票购买,Arcus Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}